Fürst-Stirum-Klinik Bruchsal
- Address
- Gutleutstr. 1-14, Klinik für Gastroenterologie, Hämato-Onkologie, Pneumonologie, Infektiologie und Intensivmedizin in Bruchsal, 76646 Bruchsal, Germany
Fürst-Stirum-Klinik Bruchsal - Colorectal Cancer Research Center
Fürst-Stirum-Klinik Bruchsal is a distinguished clinical research center dedicated to advancing treatment strategies for gastrointestinal malignancies. The center demonstrates particular expertise in conducting complex multicenter trials focused on optimizing therapeutic approaches for advanced colorectal cancer patients.
- Metastatic colorectal cancer treatment optimization
- First-line combination chemotherapy regimens
- Comparative effectiveness trials of targeted biological therapies
The facility actively participates in phase II randomized trials investigating innovative treatment combinations for metastatic colorectal cancer. Their research portfolio includes evaluating novel combinations of trifluridine/tipiracil with targeted agents such as panitumumab and bevacizumab, contributing valuable evidence to guide clinical decision-making in first-line treatment selection for patients with advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fürst-Stirum-Klinik Bruchsal
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase II Trial Comparing Trifluridine/Tipiracil with Panitumumab Versus Trifluridine/Tipiracil with Bevacizumab in Metastatic Colorectal Cancer | Charite Universitaetsmedizin Berlin KöR | Phase II | Recruiting | Oct 2021 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 1 | Unknown | 2021-10-21 | 2021-10-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.